ERBB2 and neoplasm: Moreover, Mączyńska et al. (2020) demonstrated that the administration of a IR700-based HER2-targeted affibody conjugate can drive immunogenic cancer cell death and influence the innate and adaptive anti-tumour immune response when irradiated with NIR-light.